Collegium Pharmaceutical
Collegium Pharmaceutical Inc is an American commercial-stage specialty pharmaceutical enterprise focused on the development, manufacturing, and commercialization of innovative medicines for individuals suffering from chronic pain, addiction, and other central nervous system disorders, prominently featuring abuse-deterrent formulations such as Xtampza ER and Belbuca. The company utilizes proprietary drug delivery technologies to create pharmaceutical products designed to deter abuse while providing effective therapeutic relief. Its core business operations encompass specialty pharmaceutical manufacturing, clinical trial execution, commercial distribution, and FDA regulatory navigation. Revenue is derived primarily from direct prescription pharmaceutical product sales within the United States. Collegium Pharmaceutical holds a leading market position in abuse-deterrent pain management therapeutics. The company is headquartered in Needham, Massachusetts, United States, and its common stock trades on the Nasdaq Global Select Market.
4 of the funds FundTelligence covers report a position in Collegium Pharmaceutical.
- Legal name
- COLLEGIUM PHARMACEUTICAL INC
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
Funds holding Collegium Pharmaceutical
- JPM Global Value Fund — JPM · 0.15 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.05 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.01 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)